Join our campaign to have ribociclib and palbociclib subsidised in Australia

Sent my letter  Lending my Support to Sue Dunlevy, Journalist and the atached article has popped up in papers today.  Hereunder is my response to article which had gone on Facebook:-

I am a cancer survivor for 12 years and I firmly believe that I am here because of new anti-body technology, Herceptin and now Kadcyla. I look forward to seeing new technologies such as these fast tracked. Cancer patients do not have time to wait. Conventional regimes of chemotheraphy can be antiquated and cruel, and at worst, ineffective. I am watching this space with great interest these technologies can give quality of life, enabling cancer survivors to remain part of mainstream society, continue to work and be a contributor to society. Current cancer regimes interrupt one's life significantly due to down time and terrible side effects, having diabolical consequences on people's ability to continue working and living a normal life.

I believe the Pharmaceutical Benefits Scheme personnel are meeting this week to consider new technology drugs. I for one hope that CDK inhibitors Ribociclib (Kisqali) and Palbociclib (Ibrance) become available for my fellow breast cancer survivors so they too can have the benefits and hope for a good life that has availed me.

Australian cancer patients need, expect and deserve timely access to the latest cancer drugs under a system that is fair, equitable and in a sustainable way.

Thank you

Karen_C
Cancer survivor 12 years

perthnow.com.au — CHEMOTHERAPY could become a thing of the past for up to two in three cancer patients with the government looking at subsidising breakthrough new immunotherapies across multiple cancers. The medicines called programmed-death ligand 1 (PDL1) therapies — like Keytruda which dramatically extended the life of Liberal Party fundraiser Ron Walker, and Opdivo — use the body’s own immune system to fight cancer.